Role of the EZH2 histone methyltransferase as a therapeutic target in cancer
- 1 September 2016
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 165, 26-31
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitorsOncotarget, 2015
- Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitorsOncogene, 2015
- Radiotherapy for recurrent small cell carcinoma of the ovary: A case report and review of the literatureGynecologic Oncology Reports, 2015
- Recurrent SMARCA4 mutations in small cell carcinoma of the ovaryNature Genetics, 2014
- Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell GrowthChemistry & Biology, 2013
- Inhibition of Enhancer of Zeste Homolog 2 (EZH2) Expression Is Associated With Decreased Tumor Cell Proliferation, Migration, and Invasion in Endometrial Cancer Cell LinesInternational Journal of Gynecological Cancer, 2013
- High‐resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumorsGenes, Chromosomes and Cancer, 2012
- MEK–ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypesOncogene, 2011
- EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancerThe EMBO Journal, 2003
- Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomasCancer, 2001